Compare Lloyds Banking Group Plc American Depositary Shares (LYG) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lloyds Banking Group Plc American Depositary Shares vs Repligen Corporation Common Stock — how do they compare? Lloyds Banking Group Plc American Depositary Shares trades at $5.65 (market cap $79.61B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: Lloyds Banking Group Plc American Depositary Shares is far larger — about 7× Repligen Corporation Common Stock's market cap, and Lloyds Banking Group Plc American Depositary Shares pays a 3.99% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lloyds Banking Group Plc American Depositary Shares for 3 Days and Repligen Corporation Common Stock for 0 Days on average.
| LYG | RGEN | |
|---|---|---|
Market Cap | $79.61B | $11.31B |
Volume | 13,734,654 | 1,216,919 |
Sector | Financials | Health |
52-Week High | $6.28 | $194.57 |
52-Week Low | $4.44 | $102.87 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $102.02B | $11.20B |
Dividend Yield | 3.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lloyds Banking Group (LYG) trades at $5.50, up 0.73% on the day, with a bearish technical signal from moving averages. The company reported strong profitability with a net income margin of 24.5% and has beaten earnings estimates in two of the last three quarters. Recent news highlights its 2030 growth plan emphasizing AI and efficiency, with potential acquisition interest in Aldermore.
The outlook is mixed: analyst consensus is bullish (58% buy ratings), but technicals and a recent earnings miss pose near-term risks. Upside catalysts include strategic investments and resilient UK consumers, while risks involve economic sensitivity and competitive pressures. The stock's valuation appears reasonable with a P/E of 12.98.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lloyds Banking Group Plc American Depositary Shares
Lloyds Banking Group provides retail, commercial, and insurance services in the United Kingdom. Its banking brands include Lloyds Bank, Halifax, and Bank of Scotland.
Read more on LYG →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
